TIM-3 blockade
Antibodies against TIM-3, a checkpoint on exhausted T cells and myeloid cells, tested mostly with PD-1 drugs and in blood cancers.
Overview
T-cell immunoglobulin and mucin domain 3 (TIM-3, gene HAVCR2) marks the most exhausted T cells and is also expressed on leukaemic stem cells and myeloid cells. Antibodies such as sabatolimab and cobolimab have been tested with PD-1 blockade in solid tumours and with hypomethylating agents in myelodysplastic syndromes and acute myeloid leukaemia; the STIMULUS programme in MDS did not meet its endpoints, and development is concentrated in combination settings.
How it works
Antibodies block TIM-3 binding to galectin-9, phosphatidylserine and CEACAM1, restoring T-cell and innate immune function.
- Targets both adaptive and innate immune brakes
- Expressed on leukaemic stem cells
- Phase 3 MDS trials negative
- Solid tumour activity modest so far
Latest papers
topQuery for this technology: (TITLE:"TIM-3 blockade" OR ABSTRACT:"TIM-3 blockade") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TIM-3 blockade, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialEfficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
Shares Cobolimab, Non-small-cell lung cancer.
- CompanyOrca Biosystems
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- CompanyTreadwell Therapeutics
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TreatmentAZD7789
Shares TIM-3, Non-small-cell lung cancer.
- PersonMarc H.G.P. Raaijmakers
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- PersonUwe Platzbecker
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- Companymedac
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TreatmentDorocubicel (UM171-expanded cord blood)
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.